Trial Profile
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Acronyms LIBERTY AD PED OLE
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 01 Mar 2024 Results assessing clinical data of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis published in the Pediatric Dermatology
- 26 Sep 2023 Results of long-term safety, efficacy, and pharmacokinetics of dupilumab in children with severe AD, published in the Dermatology and Therapy
- 21 Mar 2023 Results (n=180) assessing the long term 52-week laboratory safety for dupilumab-treated children aged 6 months to 5 years with moderate-to-severe atopic dermatitis, presented at the American Academy of Dermatology annual Meeting 2023.